Contents 2 min read

Claim and source comparison

Comparison limited to the Viola 1995 animal/laboratory abstract, Amsterdam 2009 chamomile-extract trial abstract and NCCIH chamomile safety information. Not a full clinical review of pure apigenin.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Animal study

Viola et al. (1995) examined apigenin affinity for a benzodiazepine binding site in the laboratory and anxiety-like behavior measures in mice. Some experimental doses produced no sedation; a tenfold increase produced a mild sedative effect.

Mouse behavior and receptor binding are not evidence of human sleep treatment or a clinical GABA-A effect. Animal doses were not converted into human doses or a verified interaction with sedative medicines.

Source 2 · Abstract read

Human randomized controlled trial

Amsterdam et al. (2009) randomized 57 people with mild-to-moderate generalized anxiety disorder to chamomile extract or placebo for eight weeks. Change in the primary HAM-A score favored extract (P = 0.047); the study did not test pure apigenin.

This is a small, short preliminary trial, underpowered for small secondary-outcome differences. A chamomile-extract result cannot be transferred to pure apigenin, chamomile tea or insomnia treatment.

Source 3 · Abstract read

Official safety summary

NCCIH describes serious allergic reactions and reported warfarin interactions for chamomile; possible sedative interactions are theoretical. This information concerns chamomile products, not the clinical safety profile of pure apigenin.

Plant safety information does not prove identical risks or safety for an isolated molecule. The sources read do not establish long-term, pregnancy/breastfeeding or medication-combination safety of pure apigenin.

Source 4 · Official summary read

Our evidence and source methodology

What is Apigenin?

Apigenin is a flavonoid found in chamomile and other plants. Findings on calming mechanisms are mostly preclinical; chamomile extract trials do not establish pure apigenin as a sleep or anxiety treatment.

Mechanism of Effect

Viola et al. (1995) examined apigenin affinity for a benzodiazepine binding site in the laboratory and anxiety-like behavior measures in mice. Some experimental doses produced no sedation; a tenfold increase produced a mild sedative effect.

Mouse behavior and receptor binding are not evidence of human sleep treatment or a clinical GABA-A effect. Animal doses were not converted into human doses or a verified interaction with sedative medicines.

Clinical Evidence

Amsterdam et al. (2009) randomized 57 people with mild-to-moderate generalized anxiety disorder to chamomile extract or placebo for eight weeks. Change in the primary HAM-A score favored extract (P = 0.047); the study did not test pure apigenin.

This is a small, short preliminary trial, underpowered for small secondary-outcome differences. A chamomile-extract result cannot be transferred to pure apigenin, chamomile tea or insomnia treatment.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

The sources reviewed do not establish a validated sleep or anxiety dose, onset or oral half-life for pure apigenin. Chamomile tea, plant extract and the isolated molecule cannot be treated as equivalent.

These sources do not establish clinical efficacy or safety of pure apigenin combined with melatonin. Different substance classes do not establish complementarity or a personal combination recommendation.

Safety and Side Effects

NCCIH describes serious allergic reactions and reported warfarin interactions for chamomile; possible sedative interactions are theoretical. This information concerns chamomile products, not the clinical safety profile of pure apigenin.

Plant safety information does not prove identical risks or safety for an isolated molecule. The sources read do not establish long-term, pregnancy/breastfeeding or medication-combination safety of pure apigenin.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

Sources

  1. Salehi, B. et al. (2019). The therapeutic potential of apigenin. International Journal of Molecular Sciences, 20(6), 1305. (Genel derlemedir; spesifik mekanizma iddiaları için orijinal çalışmalar incelenmelidir.) PubMed · PMID 30875872
  2. Viola, H. et al. (1995). Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Medica, 61(3), 213–216. PubMed · PMID 7617761
  3. Amsterdam, J.D. et al. (2009). A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. Journal of Clinical Psychopharmacology, 29(4), 378–382. PubMed · PMID 19593179
  4. NIH NCCIH. Chamomile: Usefulness and Safety. https://www.nccih.nih.gov/health/chamomile NIH NCCIH

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions